Table 3 |
||||||||
|
Complete blood count data of men (A) and women (B) before and following three weeks of supplementation with Ambrotose AO® at a dosage of 4 capsules per day and placebo (cross-over design with a three week washout between conditions). |
||||||||
|
A |
||||||||
|
|
||||||||
|
Variable |
Trained Men Ambrotose AO® Pre |
Trained Men Ambrotose AO® Post |
Trained Men Placebo Pre |
Trained Men Placebo Post |
Untrained Men Ambrotose AO® Pre |
Untrained Men Ambrotose AO® Post |
Untrained Men Placebo Pre |
Untrained Men Placebo Post |
|
|
||||||||
|
WBC (103 μL)† |
4.5 ± 0.1 |
4.5 ± 0.2 |
5.1 ± 0.6 |
4.9 ± 0.3 |
5.7 ± 0.5 |
6.0 ± 0.4 |
5.9 ± 0.5 |
5.6 ± 0.5 |
|
RBC (106 μL)* |
4.9 ± 0.1 |
4.7 ± 0.1 |
4.9 ± 0.1 |
4.8 ± 0.1 |
4.7 ± 0.2 |
4.6 ± 0.2 |
4.6 ± 0.3 |
4.6 ± 0.2 |
|
Hemoglobin (g·dL-1)* |
14.7 ± 0.3 |
13.3 ± 0.5 |
14.8 ± 0.4 |
14.6 ± 0.3 |
14.8 ± 0.5 |
14.6 ± 0.5 |
14.6 ± 0.6 |
14.4 ± 0.4 |
|
Hematocrit (%)†* |
43.3 ± 0.8 |
41.8 ± 1.1 |
43.5 ± 1.0 |
42.3 ± 0.5 |
43.0 ± 1.0 |
41.9 ± 1.2 |
42.2 ± 2.0 |
41.2 ± 1.3 |
|
MCV (fL)** |
88.7 ± 2.2 |
89.0 ± 2.5 |
88.3 ± 2.3 |
88.3 ± 2.2 |
91.2 ± 2.6 |
90.8 ± 2.3 |
91.6 ± 2.2 |
91.0 ± 2.5 |
|
MCH (pg)** |
30.2 ± 1.0 |
30.5 ± 1.0 |
29.9 ± 1.0 |
30.3 ± 0.9 |
31.4 ± 1.0 |
31.7 ± 1.0 |
31.7 ± 1.0 |
31.9 ± 1.1 |
|
MCHC (g·dL-1)** |
34.0 ± 0.4 |
34.2 ± 0.2 |
33.9 ± 0.4 |
34.4 ± 0.4 |
34.5 ± 0.4 |
34.9 ± 0.3 |
34.5 ± 0.3 |
35.0 ± 0.4 |
|
RDW (%)** |
13.8 ± 0.4 |
13.2 ± 0.3 |
13.6 ± 0.3 |
13.5 ± 0.3 |
13.0 ± 0.2 |
13.1 ± 0.2 |
12.9 ± 0.2 |
12.9 ± 0.2 |
|
Platelets (103 μL)* |
208.0 ± 16.7 |
204.0 ± 13.9 |
214.4 ± 16.1 |
211.4 ± 21.7 |
217.6 ± 20.4 |
203.2 ± 21.0 |
208.0 ± 24.5 |
209.6 ± 24.3 |
|
Neutrophils (%) |
51.1 ± 4.5 |
50.0 ± 3.4 |
52.7 ± 4.9 |
51.0 ± 4.6 |
54.2 ± 2.6 |
58.0 ± 4.6 |
52.8 ± 2.1 |
53.6 ± 3.6 |
|
Lymphocytes (%) |
36.0 ± 3.8 |
37.4 ± 3.2 |
36.0 ± 4.4 |
36.4 ± 4.3 |
32.6 ± 2.1 |
30.2 ± 4.1 |
34.2 ± 1.3 |
33.5 ± 2.9 |
|
Monocytes (%)† |
7.7 ± 0.6 |
8.6 ± 0.8 |
7.6 ± 0.6 |
8.3 ± 0.5 |
7.4 ± 0.9 |
7.2 ± 1.2 |
7.0 ± 0.5 |
7.1 ± 0.9 |
|
Eosinophils (%)* |
4.9 ± 1.8 |
3.7 ± 0.8 |
3.1 ± 0.7 |
3.9 ± 0.6 |
5.2 ± 1.6 |
4.0 ± 1.0 |
5.8 ± 1.8 |
5.3 ± 1.8 |
|
Basophils (%) |
0.3 ± 0.2 |
0.3 ± 0.2 |
0.6 ± 0.2 |
0.4 ± 0.2 |
0.6 ± 0.2 |
0.6 ± 0.2 |
0.2 ± 0.2 |
0.5 ± 0.2 |
|
|
||||||||
|
B |
||||||||
|
|
||||||||
|
Variable |
Trained Women Ambrotose AO® Pre |
Trained Women Ambrotose AO® Post |
Trained Women Placebo Pre |
Trained Women Placebo Post |
Untrained Women Ambrotose AO® Pre |
Untrained Women Ambrotose AO® Post |
Untrained Women Placebo Pre |
Untrained Women Placebo Post |
|
|
||||||||
|
WBC (103 μL)† |
5.1 ± 1.0 |
5.2 ± 0.7 |
4.7 ± 0.4 |
5.3 ± 0.7 |
5.6 ± 0.5 |
4.9 ± 0.3 |
5.0 ± 0.4 |
6.0 ± 0.8 |
|
RBC (106 μL)* |
4.2 ± 0.1 |
4.1 ± 0.1 |
4.2 ± 0.1 |
4.2 ± 0.1 |
4.2 ± 0.1 |
4.1 ± 0.1 |
4.2 ± 0.1 |
4.2 ± 0.2 |
|
Hemoglobin (g·dL-1)* |
13.4 ± 0.4 |
12.8 ± 0.3 |
13.2 ± 0.1 |
13.2 ± 0.2 |
12.5 ± 0.3 |
12.1 ± 0.4 |
12.3 ± 0.5 |
12.4 ± 0.6 |
|
Hematocrit (%)†* |
38.8 ± 1.0 |
37.1 ± 0.9 |
38.6 ± 0.4 |
37.9 ± 0.6 |
36.9 ± 0.8 |
35.0 ± 0.8 |
36.6 ± 1.4 |
36.5 ± 1.5 |
|
MCV (fL)** |
91.9 ± 1.7 |
91.4 ± 1.8 |
91.4 ± 2.0 |
90.8 ± 2.0 |
87.1 ± 1.2 |
85.8 ± 0.7 |
86.5 ± 0.9 |
86.2 ± 0.9 |
|
MCH (pg)** |
31.7 ± 0.7 |
31.6 ± 0.7 |
31.1 ± 0.7 |
31.5 ± 0.7 |
29.6 ± 0.4 |
29.7 ± 0.4 |
29.0 ± 0.4 |
29.3 ± 0.6 |
|
MCHC (g·dL-1)** |
34.6 ± 0.2 |
34.6 ± 0.2 |
34.1 ± 0.2 |
34.7 ± 0.2 |
33.9 ± 0.2 |
34.6 ± 0.3 |
33.6 ± 0.2 |
33.9 ± 0.4 |
|
RDW (%)** |
13.1 ± 0.3 |
13.3 ± 0.3 |
13.2 ± 0.2 |
13.5 ± 0.3 |
13.3 ± 0.5 |
13.6 ± 0.6 |
13.7 ± 0.6 |
13.7 ± 0.6 |
|
Platelets (103 μL)* |
234.3 ± 20.0 |
229.1 ± 17.1 |
246.1 ± 23.6 |
236.1 ± 18.8 |
256.9 ± 29.9 |
259.2 ± 25.4 |
254.8 ± 35.6 |
267.0 ± 34.2 |
|
Neutrophils (%) |
54.1 ± 5.5 |
56.3 ± 4.8 |
57.7 ± 4.7 |
58.8 ± 3.9 |
57.3 ± 3.5 |
56.0 ± 2.0 |
53.8 ± 3.2 |
58.3 ± 3.4 |
|
Lymphocytes (%) |
34.3 ± 4.9 |
31.0 ± 4.0 |
30.6 ± 4.4 |
29.3 ± 3.2 |
34.3 ± 3.5 |
35.8 ± 1.8 |
36.5 ± 2.6 |
32.5 ± 3.0 |
|
Monocytes (%)† |
8.0 ± 0.9 |
9.0 ± 1.0 |
7.3 ± 0.4 |
8.4 ± 0.6 |
6.1 ± 0.5 |
6.0 ± 0.5 |
6.2 ± 0.7 |
5.5 ± 0.8 |
|
Eosinophils (%)* |
3.0 ± 0.5 |
3.3 ± 0.9 |
3.4 ± 0.6 |
3.0 ± 0.6 |
1.7 ± 0.5 |
1.8 ± 0.2 |
3.0 ± 0.6 |
2.7 ± 0.5 |
|
Basophils (%) |
0.6 ± 0.2 |
0.4 ± 0.2 |
1.0 ± 0.0 |
0.5 ± 0.2 |
0.6 ± 0.2 |
0.3 ± 0.2 |
0.5 ± 0.2 |
0.5 ± 0.2 |
|
|
||||||||
|
Values are mean ± SEM. † Training status effect: WBC (p = 0.02); Hematocrit (p = 0.02); Monocytes (p = 0.0001) * Sex effect: RBC (p < 0.0001); Hemoglobin (p < 0.0001); Hematocrit (p < 0.0001); Platelets (p = 0.004); Eosinophils (p = 0.002) ** Sex × training status effect: MVC (p = 0.0002); MCH (p < 0.0001); MCHC (p = 0.008); RDW (p = 0.03) No other statistically significant differences were noted (p > 0.05). |
||||||||
|
Bloomer et al. Nutrition Journal 2010 9:49 doi:10.1186/1475-2891-9-49 |
||||||||
